FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			of Section So(ii) of the investment Company Act of 1940					
1. Name and Addre Loose Christ	ess of Reporting Pers opher R.	con*	2. Issuer Name and Ticker or Trading Symbol <u>Frequency Therapeutics, Inc.</u> [FREQ]		ationship of Reporting Pers k all applicable) Director	10% Owner		
(Last) C/O FREQUEN	(First) ICY THERAPEU	(Middle) TICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 07/07/2023	X	Officer (give title below) Chief Scientific (Other (specify below) Officer		
75 HAYDEN AVE, SUITE 300			4. If Amendment, Date of Original Filed (Month/Day/Year) 07/11/2023	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) LEXINGTON	МА	02421		X	Form filed by One Repo Form filed by More than Person	8		
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication					
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is interest to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	07/07/2023		s		1,306 ⁽¹⁾	D	\$0.36 ⁽²⁾	203,689 ⁽³⁾	D		
Common Stock	07/10/2023		S		1,304 ⁽¹⁾	D	\$0.37 ⁽⁴⁾	202,385	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(cigi, pu	, oui	, ,	vante		0010113, 0			ounties	<i>'</i>)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		e and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.34 to \$0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. Includes 6,329 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.37 to \$0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Remarks:

This Form 4/A is being filed to remove the vesting of the Restricted Stock Units in Table I and Table II and to correct the aggregate securities following the transaction in column 5 of Table I.

<u>/s/ James P. Abely, Attorney-</u>	
<u>in-Fact for Christopher R.</u>	07/12/2023
Loose	

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number:	3235-0287					
Estimated average burden						
hours ner resnonse.	0.5					